Human T-lymphotropic Virus Vaccine

Creative Biolabs is a world leader in the field of vaccine development and can offer high-quality viral vaccines for use in prevention of viral infections. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. Adult T cell leukaemia / lymphoma is a human T cell leukaemia virus-infected T cell malignancy with poor prognosis. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services against human T-lymphotropic virus.

Human T-lymphotropic Virus Vaccine - Creative Biolabs

Human T-lymphotropic virus (HTLV), the first retrovirus identified in humans, is an enveloped retrovirus belonging to the Deltaretrovirus genus of the Retroviridae family. Retroviruses use reverse transcriptase to produce DNA from RNA and the DNA is subsequently incorporated into the host’s genome. HTLV contains two single-stranded, equal, positive ribonucleic acid (RNA) molecules. It has four types, of which only HTLV-1 and HTLV-2 are associated with cases of disease and HTLV-1 is the most clinically significant of the two. HTLV predominantly affects T lymphocytes and causes a type of cancer called adult T-cell leukemia / lymphoma (ATL). The main transmitted ways of HTLV are sexual, vertical, blood transfusion or the use of contaminated needles and/or syringes.

Subunit BLV vaccines

Design a multiepitope subunit vaccine which may have the ability to protect from HTLV-1 infection is an aim to contribute to the path of cancer vaccine development. Px gene actively participates in the open-reading-frame transcription and hence encodes for five regulatory proteins namely p12, p13, p30, rex, and Tax. In this way, structural and regulatory proteins of HTLV-1 was selected and subjected to predict the B-cell, cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes. Therefore, these predicted epitopes can be the candidates to conjugate together along with suitable adjuvants and linkers to construct the subunit vaccine. For example, the designed vaccine consists of the immunogenic B-cell and T-cell epitopes instead of any viral live component and hence reduces the risk factors of pathogenic reversal. Moreover, a soluble recombinant surface glycoprotein (gp46) can be fused to the Fc region of human IgG (sRgp46-Fc) as an immunogen to form a vaccine against BLV.

Peptide Vaccines

A peptide vaccine construct, designated MVFMF2, comprises amino acids (aa) 175-218 of HTLV-1 surface envelope glycoprotein protein gp46 linked by a four-residue turn (GPSL) to a promiscuous T-cell epitope from the measles virus fusion protein (MVF, aa 288-302). This vaccine derived from gp46 to mimic the native protein and can elicit a protective immune response. When administered with adjuvant nor-MDP was immunogenic in an outbred population of both rabbits and mice. Furthermore, the peptide construct was encapsulated in biodegradable microspheres to eliminate booster immunization. Additionally, inoculated rabbits exhibited enhanced reactivity to viral antigens compared to non-vaccinated controls. The results indicate that the peptide vaccine can be an option in the future development of vaccines to HTLV-1.

DNA Vaccines

A DNA vaccine with Tax-coding DNA against HTLV-1 tumor was under development. This vaccine can induce HTLV-1 Tax-specific CTL immunity by examining the effects in the rat ATL-like disease model, and these CTLs were able to lyse HTLV-1 infected syngeneic T cells in vitro. Adoptive transfer of these immune T cells effectively inhibited the in vivo growth of HTLV-1-transformed tumor in rats inoculated with a rat HTLV-1 infected T cell line. These results indicated a promising effect for DNA vaccine with HTLV-1 Tax against HTLV-1 tumor development in vivo.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against human T-lymphotropic virus. Our scientists are confident in offering the best services and products upon request!


All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.


Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONTACT US

USA

Tel:
Fax:
Email:
UK

Tel:
Email:
Germany

Tel:
Email:


Follow us on